Improvement of Glucose Tolerance in Type 2 Diabetic Patients: Traditional vs. Modern Insulin Regimens (Results from the Austrian Biaspart Study)

Abstract

Objective: Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin regimens have not been evaluated yet. The aim of the present study was to investigate whether meal-related (breakfast, lunch, dinner) application of biphasic insulin aspart 30 (BIAsp 30) provides better glycaemic control than administration of biphasic human insulin 30 (BHI 30) twice per day. Research design and methods: In a multi-centre, randomized, open-label parallel trial, a total of 177 patients with type 2 diabetes mellitus were exposed to the two different insulin regimens described above over a study period of 24 weeks. HbA_1c and glycemic exposure parameters were measured at predefined intervals. Results: The mean difference between treatment groups in HbA_1c after 24 weeks of treatment was 0.08 % (p = 0.6419). Analysing the 7-point blood-glucose (BG) profiles, significant differences in BG levels were observed after lunch (156 vs. 176 mg/dl, p = 0.0289), before dinner (142 vs. 166 mg/dl p = 0.006) and after dinner (154 vs. 182 mg/dl p = 0.002) in favour of BIAsp 30 insulin. Prandial BG increment was lower in the BIAsp 30 group at breakfast (p = 0.057) and lunch (p < 0.0005). No difference was found regarding safety parameters in the two treatment groups. Conclusions: This study demonstrates that meal-related BIAsp 30-insulin maintains postprandial BG control more effectively than traditional BHI 30 insulin twice per day in type 2 diabetic patients.

Type 2 diabetes mellitus - insulin analogues - premixed insulin formulations - postprandial glucose - meal-based insulin regimens

References

• 1 UK Prospective Diabetes Study Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 2 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optional diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 Suppl 2 B21-B29
• 3 Turner H E, Matthews D R. The use of fixed-mixture insulins in clinical practice.  Eur J Clin Pharmacol. 2000;  56 19-25
• 4 Yki-Jarvinen H, Kauppila M, Kujansuu E, Lathi J, Marjanen T, Niskanen L. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.  N Engl J Med. 1992;  327 1426-1433
• 5 Berger M, Heinemann L. Are presently available insulin anlogues clinically beneficial?.  Diabetologia. 1997;  40 91-96
• 6 Del Prato S. Post-prandial hyperglycaemia. the necessity for better control.  Int J Clin Pract. 2000;  Suppl 112 3-8
• 7 Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetic patients.  Diabetes Care. 2001;  24 758-767
• 8 Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.  Diabetes Care. 1997;  20 1612-1614
• 9 Jacobsen L V, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.  Eur J Clin. 2000;  56 399-403
• 10 Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kohlendorf K, Madsbad S. Improved postprandial glycaemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.  Diabetes Care. 2002;  25 883-888
• 11 Lindholm A, McEwen J, Anders P R. Improved postprandial glycemic control with insulin aspart: a randomized double-blind cross-over trial in type 1 diabetes.  Diabetes Care. 1999;  22 801-805
• 12 Jacobsen L V, Sogaard Rosenfalck A M, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen K F. et al . Improved postprandial glycaemic control with insulin aspart in type 2 diabetes patients treated with insulin.  Acta Diabetol. 2000;  37 41-46
• 13 Boehm B O, Home P D, Behrend C, Kamp N M, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and type 2 diabetic patients.  Diabet Med. 2002;  19 393-399
• 14 McSorley P T, Bell P M, Jacobsen L V, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind crossover study in adults with type 2 diabetes mellitus.  Clin Ther. 2002;  24 530-539
• 15 Savoca M, Miller C. Food selection and eating patterns: themes found among people with type 2 diabetes mellitus.  J Nutr Educ. 2001;  33 224-233
• 16 Bolli G B. Clinical strategies for controlling peaks and valleys: type 1 diabetes.  Int J Clin Pract. 2002;  Suppl. 129 65-74
• 17 Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin Lispro formulation.  Diabetes Care. 1999;  22 1258-1261
• 18 Winkler G, Doring A, Keil U. Meal patterns in middle-aged men in Southern Germany: results from the MONICA Augsburg dietary survey 1984/85.  Appetite. 1999;  32 33-37
• 19 Schernthaner G, Kopp H P, Ristic S, Muzyka B, Peter L, Miteregger G. Metabolic control in patients with type 2 diabetes using Humalog MIX50 injected three times daily: Crossover Comparison with human insulin 30/70.  Horm Metab Res. 2004;  36 188-193
• 20 Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursions with biphasic insulin Aspart 30 injected immediately before a meal.  Diabet Med. 2004;  21 500-501
• 21 Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen J S. Comparison of thrice daily “high” vs. “medium” premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.  Diabetes, Obesity and Metabolism. 2003;  5 438-445
• 22 Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna R C, Muggeo M. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes.  Diabetes Care. 2001;  24 2023-2029
• 23 Donahue R P, Abbot R D, Reed D M, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry (Honolulu Heart Program).  Diabetes. 1997;  36 689-692
• 24 Gerich J E. Clinical significance, pathogenesis, and management of postprandial hyperglycaemia.  Arch Intern Med. 2003;  163 1306-1316
• 25 The DECODE study group on behalf of the European Diabetes Epidemiology Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-h diagnostic criteria.  Arch Intern Med. 2001;  161 397-404
• 26 Soonthornpun S, Rattarsarn C, Leelatwatana R, Setasuban W. Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having nearnormal fasting glucose levels.  Diabetes Res Clin Pract. 1999;  46 23-27
• 27 Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study.  Diabetes Care. 1998;  21 1236-1239
• 28 Bloomgarden Z T. Cardiovascular Disease and Diabetes.  Diabetes Care. 2003;  26 230-237
• 29 Ceriello A, Cavarape A, Martinelli L, DaRos R, Marrat G, Quagliaro L, Piconi L, Assaloni R, Motz E. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart.  Diabet Med. 2004;  21 171-175
• 30 American Diabetes Association . Position Statements: Standards of Medical Care in Diabetes.  Diabetes Care. 2004;  27 Suppl 1 15-35
• 31 Cryer P h, Davis S N, Shamoon H. Hypoglycemia in Diabetes.  Diabetes Care. 2003;  26 1902-1912
• 32 Leese G P, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier B M, Moris A D. Frequency of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 Diabetes: A population-based study of health service resource use.  Diabetes Care. 2003;  26 1176-1180